Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115513 | 0.90 | NPC1 (0.38) | ADAMTS4MMP2MMP13ADAM17MMP14 | |
| SCHEMBL3516007 | 0.86 | ADAMTS4 (0.42) | ADAMTS4MMP2MMP13ADAM17MMP14 | |
| SCHEMBL28886134 | 0.85 | DRD2 (0.42) | HTR2AHTR2C | |
| SCHEMBL30823619 | 0.84 | GAA (0.41) | GAAHSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL1180196 | 0.84 | GAA (0.41) | GAAHSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL7526268 | 0.83 | CYP2C9 (0.35) | GAANPC1PKMHTTEPHX2 | |
| SCHEMBL8945001 | 0.83 | CYP2C9 (0.35) | GAANPC1PKMHTTEPHX2 | |
| SCHEMBL28624344 | 0.82 | MCOLN3 (0.34) | GAAHSD17B10EPHX2CYP2D6MEN1 | |
| SCHEMBL5718625 | 0.80 | GAA (0.39) | GAAHSD17B10HTTCYP3A4MEN1 | |
| SCHEMBL816601 | 0.80 | GAA (0.39) | GAAHSD17B10CYP3A4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107098886-B | Prazinone-containing quinazolinone PARP-1/2 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-07-14 | — | — | CN | disclosed |
| EP-2906539-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2017-06-21 | — | — | EP | disclosed |
| US-9475802-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-10-25 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2906539-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| WO-2007143597-A9 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2029572-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2029572-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007143597-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156615-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | ADAMTS4 2367/4885MMP2 1173/4885MMP13 1303/4885 |
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | ADAMTS4 2367/4885MMP2 1173/4885MMP13 1303/4885 |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, MAVS | ADAMTS4 4090/4885MMP2 1901/4885MMP13 3895/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | ADAMTS4 2367/4885MMP2 1173/4885MMP13 1303/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | ADAMTS4 2367/4885MMP2 1173/4885MMP13 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.